Collaboration with Shonan iPark and Kamakura General Hospital expands global reach!
Korean induced pluripotent stem cell platform company ‘YIPSCELL’ is rushing to bring its key pipeline, osteoarthritis cell therapy ‘MIUChon’, to Japan.
Hosted by ‘Shonan iPark’ in Japan, YIPSCELL said it discussed the progress of the MIUChon clinical trial in osteoarthritis patients in Japan with Kamakura General Hospital.
Japan was the first country in the world to develop induced pluripotent stem cells (iPSCs), and is home to more than 20 clinical trials of various iPSC-derived cell therapies. YIPSCELL plans to secure clinical results for YIPSCELL’s technology and products in global markets, starting with Japan, as MIUChon enters clinical trials in the country.
“The osteoarthritis market is a large market not only in Japan, but also globally, and we will actively cooperate with YIPSCELL’s MIUChon clinical trial,” said Dr. Kobayashi, President of Kamakura General Hospital.
“YIPSCELL is planning to enter the Japanese market with a focus on Shonan iPark and Kamakura General Hospital, and we will continue to actively build a collaborative relationship with them,” said Ji-Hyun Joo, CEO of YIPSCELL.
Building on this collaboration, YIPSCELL will focus on securing clinical results and communicating MIUChon’s technology to global markets.